NO971438D0 - Mikropartikler - Google Patents

Mikropartikler

Info

Publication number
NO971438D0
NO971438D0 NO971438A NO971438A NO971438D0 NO 971438 D0 NO971438 D0 NO 971438D0 NO 971438 A NO971438 A NO 971438A NO 971438 A NO971438 A NO 971438A NO 971438 D0 NO971438 D0 NO 971438D0
Authority
NO
Norway
Prior art keywords
microparticles
Prior art date
Application number
NO971438A
Other languages
English (en)
Norwegian (no)
Other versions
NO971438L (no
Inventor
Andrew Derek Sutton
Richard Alan Johnson
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of NO971438L publication Critical patent/NO971438L/no
Publication of NO971438D0 publication Critical patent/NO971438D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO971438A 1994-09-29 1997-03-26 Mikropartikler NO971438D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94307126 1994-09-29
PCT/GB1995/002279 WO1996009814A1 (fr) 1994-09-29 1995-09-26 Microparticules sechees par pulverisation utilisees comme excipient therapeutique

Publications (2)

Publication Number Publication Date
NO971438L NO971438L (no) 1997-03-26
NO971438D0 true NO971438D0 (no) 1997-03-26

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971438A NO971438D0 (no) 1994-09-29 1997-03-26 Mikropartikler

Country Status (16)

Country Link
EP (1) EP0783298A1 (fr)
JP (1) JPH10506406A (fr)
KR (1) KR970705979A (fr)
AU (1) AU701440B2 (fr)
BR (1) BR9509171A (fr)
CA (1) CA2199954A1 (fr)
CZ (1) CZ92497A3 (fr)
FI (1) FI971332A0 (fr)
HU (1) HUT77373A (fr)
MX (1) MX9702357A (fr)
NO (1) NO971438D0 (fr)
NZ (1) NZ292980A (fr)
PL (1) PL319600A1 (fr)
RU (1) RU2147226C1 (fr)
WO (1) WO1996009814A1 (fr)
ZA (1) ZA958239B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
WO1997044015A1 (fr) * 1996-05-17 1997-11-27 Andaris Limited Microparticules et utilisation de ces dernieres pour soigner des plaies
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB9615435D0 (en) * 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
EP0949932A1 (fr) * 1996-10-19 1999-10-20 Quadrant Healthcare (UK) Limited Utilisation de microcapsules creuses a des fins diagnostiques et therapeutiques
WO1998029096A1 (fr) 1996-12-31 1998-07-09 Inhale Therapeutic Systems Medicament hydrophobe projete par aerosol
EP1498115A1 (fr) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Préparation de particules pour inhalation
EP0954282B1 (fr) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation de particules pour inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
AU756693B2 (en) * 1997-09-29 2003-01-23 Novartis Ag Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
JP2003524437A (ja) * 1998-02-20 2003-08-19 エラン・ドラッグ・デリバリー・リミテッド 治療に用いるためのフィブリノーゲンを含んでなる生成物
EP1273290A1 (fr) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Particules poreuses de grande taille émises par inhalateur
ES2198922T3 (es) * 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
ES2238271T3 (es) * 1999-04-21 2005-09-01 1355540 Ontario Inc. Formulaciones de metacolina o histamina para detectar asma.
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
DE60020732T2 (de) 1999-12-20 2006-05-11 Kerkhof, Nicholas J., Rio Vista Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
EP1351704B1 (fr) * 2000-12-21 2007-03-07 Nektar Therapeutics Compositions de recepteur de l'interleukine 4 en poudre stables au stockage
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
ATE401058T1 (de) 2001-11-01 2008-08-15 Nektar Therapeutics Sprühtrocknungsverfahren
EP1458360B1 (fr) 2001-12-19 2011-05-11 Novartis AG Administration pulmonaire d'aminoglycosides
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003299795A1 (en) 2002-12-20 2004-07-22 Xeris Pharmaceuticals, Inc. Intracutaneous injection
AU2004251623B2 (en) 2003-05-28 2010-03-18 Novartis Ag Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
US8075919B2 (en) 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
CA2566075A1 (fr) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres contenant des proteines et presentant un potentiel d'injectabilite a d'importants degres de concentration de l'agent concerne
EP3590503A1 (fr) 2006-10-12 2020-01-08 The University of Queensland Compositions et procédés pour moduler les réponses immunologiques
EP2050437A1 (fr) * 2007-10-15 2009-04-22 Laboratoires SMB Compositions de poudre sèche pharmaceutiquement améliorées pour l'inhalation
UA90013C2 (ru) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Фармацевтическая композиция, содержащая инсулин, и способ его получения
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
CA2738855A1 (fr) 2008-09-29 2010-04-01 The Corporation Of Mercer University Materiau bioactif d'encapsulation de nanospheres et procede de preparation de nanospheres
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
EP2216054A1 (fr) 2009-02-06 2010-08-11 ProFibrix BV Support extravasculaire biodégradable
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
EP2435028B1 (fr) * 2009-05-28 2016-08-31 ProFibrix BV Colle de fibrine sous forme de poudre sèche
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
WO2011005756A1 (fr) 2009-07-06 2011-01-13 Puretech Ventures, Llc Administration d'agents ciblés contre des niches de microbiote
WO2011083154A1 (fr) 2010-01-08 2011-07-14 Profibrix Bv Adhésif de fibrine en poudre sèche
WO2012012460A1 (fr) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Formulations de glucagon stables pour le traitement de l'hypoglycémie
BR112013010926A2 (pt) 2010-11-01 2016-08-23 Univ Technology Sidney agentes imunomoduladores e seus usos
EP3225235B1 (fr) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Formulations stables pour injection parentérale de médicaments peptidiques
SG193389A1 (en) 2011-03-10 2013-10-30 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs
RU2013155713A (ru) 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
EP2773331B1 (fr) 2011-10-31 2016-02-10 Xeris Pharmaceuticals, Inc. Formulations stables pour injection parentérale de médicaments peptidiques
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
MX354719B (es) 2012-06-26 2018-03-16 Ge Healthcare As Preparacion de una composicion que comprende microburbujas de gas.
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
JP6328146B2 (ja) 2013-02-01 2018-05-23 グリアロジクス・インコーポレイテッドＧｌｉａｌｏｇｉｘ， Ｉｎｃ． 神経変性およびその他の疾患の治療用組成物および方法
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUE062742T2 (hu) 2014-04-04 2023-12-28 Ai Therapeutics Inc Belélegezhetõ rapamicin készítmény életkorral kapcsolatos állapotok kezelésére
ES2936067T3 (es) 2014-05-27 2023-03-14 Univ Queensland IL-22 para uso en el tratamiento de trastornos metabólicos
US11129940B2 (en) 2014-08-06 2021-09-28 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
MX2017004440A (es) 2014-10-07 2017-11-01 Lam Therapeutics Inc Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016196976A1 (fr) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Appareils d'administration de glucagon et procédés associés
WO2016201248A1 (fr) 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Utilisation de glucagon à faible dose
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017062463A1 (fr) 2015-10-05 2017-04-13 The Corporation Of Mercer University Matériau bioactif d'encapsulation de nanosphères et procédé de préparation de nanosphères
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
US20180110760A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
CN117085022A (zh) 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
WO2021090214A2 (fr) * 2019-11-04 2021-05-14 Alesco S.R.L. Berbérine bertrypanosomial®, ses compositions et leur utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606486B1 (fr) * 1992-06-12 2001-08-29 Teijin Limited Preparation pharmaceutique destinee a etre administree par les voies respiratoires
WO1993025198A1 (fr) * 1992-06-12 1993-12-23 Teijin Limited Poudre ultra-fine pour inhalation et production de cette poudre

Also Published As

Publication number Publication date
AU3530295A (en) 1996-04-19
CZ92497A3 (en) 1997-08-13
MX9702357A (es) 1997-06-28
BR9509171A (pt) 1997-09-16
RU2147226C1 (ru) 2000-04-10
FI971332A (fi) 1997-04-01
EP0783298A1 (fr) 1997-07-16
ZA958239B (en) 1996-09-30
WO1996009814A1 (fr) 1996-04-04
NO971438L (no) 1997-03-26
FI971332A0 (fi) 1997-04-01
NZ292980A (en) 1999-02-25
CA2199954A1 (fr) 1996-04-04
KR970705979A (ko) 1997-11-03
HUT77373A (hu) 1998-03-30
AU701440B2 (en) 1999-01-28
PL319600A1 (en) 1997-08-18
JPH10506406A (ja) 1998-06-23

Similar Documents

Publication Publication Date Title
NO971438L (no) Mikropartikler
NO984808D0 (no) Mikropartikler
ATA166795A (de) Bis-resorcinyltriazine
ATA147195A (de) Alkoxyphenyl-substituierte bisbenzoylphosphinoxide
ATA163695A (de) 2-hydroxyphenyltriazine
DE59501347D1 (de) Hydroxyphenylharnstoffe
ATA108995A (de) Differenzdruckakkumulator
ATA11894A (de) Stauförderbahn
DE69522495T2 (de) Naturlicherschallwiedergabegerät
BR9506519A (pt) Azatrioxaspiroalquenos
DE29501964U1 (de) Libelle
SE9403034D0 (sv) SIBAB-säkring
KR960002814U (ko) 문제지
FI1530U1 (fi) Toejningsbaenk
ATE197372T1 (de) Vorteig
FI1685U1 (fi) Skidloepningsanording
BR9401264A (pt) Prevgás
BR7400635U (pt) Entopstop
FI944829A0 (fi) Vattenreningsanordning
BR9403310A (pt) Regulex
BR7400030U (pt) Numeralfa
FI943162A0 (fi) Foensterkonstruktion
BR7401141U (pt) PortA-espoNja
BR7400053U (pt) T-compacto
BR7400062U (pt) Prato-bandeja

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application